TT303

TT303 (also referred to as TT-303) is an experimental therapeutic candidate being developed by Tempo Therapeutics, Inc. for the treatment of pan-coronavirus infections, including COVID-19. The drug is currently in the discovery stage of development. TT303 leverages Tempo's proprietary Microporous Annealed Particle (MAP) technology, which utilizes a flowable, microporous hydrogel scaffold composed of spherical microgel beads. This biomaterial platform is designed to create a porous environment that can modulate immune responses or serve as a delivery vehicle for therapeutic payloads. In the context of infectious diseases, TT303 is intended to provide broad-spectrum activity against various coronaviruses. Specific details regarding its active pharmaceutical ingredient, molecular target, and precise mechanism of action have not been publicly disclosed at this early stage.